FDA Approves Imaavy (Nipocalimab-aahu) for Warm Autoimmune Hemolytic Anemia
The FDA has approved Imaavy (nipocalimab-aahu) for warm autoimmune hemolytic anemia in patients aged 12 and older. Learn about the approval, ENERGY trial results, how Imaavy works, safety information, and what this milestone means for wAIHA treatment.
A major development has arrived for people living with warm autoimmune hemolytic anemia (wAIHA). On August 24, 2026, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved Imaavy (nipocalimab-aahu) for the treatment of wAIHA in adults and children aged 12 and older who are currently or previously treated with corticosteroids. According to Johnson & Johnson, the decision makes Imaavy the first FDA-approved treatment specifically indicated for warm autoimmune hemolytic anemia.
The approval represents an important change for a rare and potentially life-threatening blood disorder. Until now, people with wAIHA have generally been treated with corticosteroids, immunosuppressive medicines, and other approaches that were not specifically FDA-approved for the condition.
What is warm autoimmune hemolytic anemia?
Warm autoimmune hemolytic anemia is a rare autoimmune disorder in which the immune system produces antibodies that mistakenly target and destroy red blood cells. Because red blood cells carry oxygen throughout the body, their accelerated destruction can lead to anemia.
Common consequences can include severe tiredness, weakness, shortness of breath and reduced ability to perform everyday activities. The condition can also be associated with serious complications, including blood clots, kidney problems and infections.
Johnson & Johnson estimates that approximately 1 to 3 new cases of wAIHA occur per 100,000 people each year, with roughly 1 in 8,000 people living with the condition. The disease can affect people of different ages, although its incidence increases among older adults.
How does Imaavy work?
Imaavy contains nipocalimab-aahu, an immunoselective blocker of the neonatal Fc receptor, or FcRn.
FcRn plays an important role in maintaining circulating levels of immunoglobulin G, commonly called IgG. In wAIHA, some IgG antibodies are pathogenic autoantibodies that contribute to the destruction of red blood cells.
By blocking FcRn, Imaavy is designed to reduce circulating IgG, including disease-driving autoantibodies. Johnson & Johnson describes the treatment as an immunoselective approach intended to lower pathogenic antibodies while preserving important aspects of immune function.
This approach is different from broadly suppressing the immune system. The goal is to target an important mechanism involved in autoantibody-driven disease.
What did the clinical trial show?
The FDA approval was supported by the Phase 2/3 ENERGY trial, a randomized, double-blind, placebo-controlled study involving adults with warm autoimmune hemolytic anemia.
A total of 115 participants were randomized to different nipocalimab dosing regimens or placebo. Participants received double-blind treatment for 24 weeks, followed by the opportunity to enter a longer open-label extension study.
One of the most important measures was a durable hemoglobin response. This endpoint was designed to identify patients who achieved a clinically meaningful improvement in hemoglobin that was maintained over time without requiring rescue treatment.
In the approved 30 mg/kg every-four-weeks treatment group, approximately three times as many patients achieved durable hemoglobin responses compared with placebo by 24 weeks. The treatment group also experienced a mean hemoglobin increase of approximately 1 g/dL by Week 1.
The study also evaluated fatigue using the FACIT-Fatigue questionnaire. At Week 24, patients receiving the approved Imaavy regimen had a mean FACIT-Fatigue score approximately 3.5 points higher than those receiving placebo. Higher scores indicate less fatigue.
These findings are particularly relevant because anemia-related fatigue can substantially affect quality of life for people with wAIHA.
What are the potential side effects?
As with any prescription medicine, Imaavy can cause side effects and is not appropriate for everyone.
According to the safety information provided with the announcement, the most common adverse reactions reported in people with wAIHA were peripheral edema, diarrhea and fever.
Important risks include infections, allergic or hypersensitivity reactions and infusion-related reactions. Patients receiving Imaavy should be monitored for signs of infection and should tell their healthcare professional about symptoms such as fever, chills, cough, sore throat or difficulty breathing.
Serious allergic reactions can also occur. Symptoms requiring urgent medical attention can include swelling of the face, lips, mouth, tongue or throat, difficulty breathing or swallowing, hives and chest tightness.
The FDA's existing prescribing information for Imaavy also emphasizes infection monitoring and precautions concerning hypersensitivity and infusion-related reactions.
Patients should discuss their complete medical history and all medications, supplements and vaccines with their healthcare professional before treatment. Live vaccines should not be administered during treatment unless specifically advised by a healthcare professional.
Why this approval matters
The FDA approval of Imaavy is significant because wAIHA has long represented an area of substantial unmet medical need.
Before this decision, treatment commonly relied on medicines such as corticosteroids and other immunosuppressive therapies that were not specifically FDA-approved for wAIHA. These approaches can be effective for some patients, but disease control may be difficult, and prolonged immunosuppression can present additional challenges.
Imaavy introduces a therapy specifically approved for wAIHA and directed at the IgG antibodies involved in the disease process.
The approval also expands the role of nipocalimab in autoimmune disease. Imaavy was previously approved in the United States for generalized myasthenia gravis in adults and pediatric patients aged 12 and older who are positive for specific antibodies.
What patients should know
An FDA approval does not mean that Imaavy will be the right treatment for every person with wAIHA. Treatment decisions depend on factors including disease severity, previous therapies, other medical conditions and the patient's individual risk profile.
People living with warm autoimmune hemolytic anemia should speak with a hematologist or other qualified healthcare professional about whether Imaavy may be appropriate for them.
The approval is nevertheless an important milestone. For patients and families who have faced recurrent anemia, debilitating fatigue and limited treatment options, the availability of a therapy specifically approved for wAIHA could mark a new chapter in disease management.
Sources
- Johnson & Johnson, August 24, 2026
- Johnson & Johnson, June 11, 2026: Phase 2/3 ENERGY study results for Imaavy in wAIHA.
- U.S. Food and Drug Administration: FDA prescribing information for Imaavy.
- FDA Orphan Drug Database: Imaavy and nipocalimab regulatory information.
Disclaimer
This article is for general informational and educational purposes only and is not medical advice, diagnosis or treatment guidance. It should not replace advice from a qualified healthcare professional. Medication indications, dosing, safety information and regulatory status can change. Anyone considering Imaavy or any other treatment for warm autoimmune hemolytic anemia should consult their physician or hematologist and review the current FDA-approved prescribing information. Do not start, stop or change a prescription medicine without medical advice.